Investor & Media Relations

We discover and develop medicines to defeat neurodegeneration.

The science is breaking open and the time is right for an ambitious and rigorous effort to address Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. We are applying deep scientific and drug development expertise to discover effective molecular therapeutics and have engineered a proprietary technology to deliver biologic therapeutics to the brain.

With a team of experienced and passionately dedicated scientists and drug developers, we believe we can succeed in meaningfully improving the lives of patients and their families.

Denali Nasdaq

Press Releases

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 07, 2023

Read More
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Aug 30, 2023

Read More
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 08, 2023

Read More


Corporate Presentation

  • Change

  • Volume

  • Market Cap

  • Today's Open

  • Previous Close

  • Exchange


  • Today's High

  • Today's Low

  • 52 Week High

  • 52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Analyst Coverage

View detailed list of firms and analysts.

View Coverage

SEC Filing

View, download, and share all SEC Filing documents.

View Documents

Corporate Governance

View, download, and share Corporate Governance documents.

View Documents